Incyte

Incyte

Yahoo Finance • 5 days ago

2 Fast-Growing Pharmaceutical Stocks to Buy Now

Key Points Incyte has added to its pipeline through acquisitions. It anticipates four new approvals and launches through 2027. TG Therapeutics' shares are up more than 90% so far this year.10 stocks we like better than Incyte › Incyte(NA... Full story

Yahoo Finance • 18 days ago

Lilly, J&J and AbbVie Hit New Highs

This article first appeared on GuruFocus. Healthcare stocks outperformed the broader market on Friday, with Eli Lilly (NYSE:LLY), Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) among the major names hitting fresh 52-week highs. The... Full story

Yahoo Finance • 18 days ago

Lilly, J&J, AbbVie hit new 52-week highs as healthcare outperforms

[Wall Street Stock Market] meshaphoto/E+ via Getty Images Healthcare was a notable outperformer on Wall Street on Friday as several top sector components of the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]), including Eli Lilly... Full story

Yahoo Finance • 18 days ago

Acadia rises as EU backs Rett syndrome therapy

[Diagnosis Rett syndrome and tablets on a wooden table.] designer491 Acadia Pharmaceuticals (ACAD [https://seekingalpha.com/symbol/ACAD]) added ~13% on Friday after an expert panel of the EU drug regulator, the European Medicines Agency,... Full story

Yahoo Finance • 18 days ago

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failed AD, the most... Full story

Yahoo Finance • 22 days ago

Stocks Mostly Lower on Weakness in Megacap Tech and Software Stocks

The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.37%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.29%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.19%.  September E-mini S&P futures (ESU26) fell -0.34%, and... Full story

Yahoo Finance • 29 days ago

Mirum and Incyte's zilurgisertib shows positive Phase 2 data in FOP

Shares of Mirum Pharmaceuticals (MIRM [https://seekingalpha.com/symbol/MIRM]) and Incyte (INCY [https://seekingalpha.com/symbol/INCY]) are in focus after the companies delivered positive pivotal Phase 2 data for their oral FOP candidate, z... Full story

Yahoo Finance • last month

Key deals this week: GSK, Incyte, Ingredion, OpenAI, and more

[M A - concept waiting for mergers and acquisitions.3D rendering on yellow background.] fengdr Here's a list of key deals reported across sectors this week: Roku Inc. (ROKU [https://seekingalpha.com/symbol/ROKU]) soared 20% on a report t... Full story

Yahoo Finance • last month

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session... Full story

Yahoo Finance • last month

Incyte Nears Buy Point As $1.25 Billion Acquisition Expands Offerings

Biotech stock Incyte is working its way up toward a pivot at 112.29, extending a two-day winning streak. Continue Reading... Full story

Yahoo Finance • last month

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Monday afternoon, with the NYSE Healthcare Index shedding 0.4% and PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Incyte To Acquire Vega Therapeutics For Up To $2 Billion

Incyte (INCY) agreed to acquire Star Therapeutics unit Vega Therapeutics in a deal worth up to $2 bi PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

What happened According to a recent SEC filing, Nan Fung Group Holdings Ltd reduced its position in Oculis(NASDAQ:OCS) by 163,957 shares during the first quarter of 2026. The estimated value of the trade was $4.3 million, based on the qua... Full story

Yahoo Finance • last month

Incyte lymphoma therapy lifts cancer-free survival by 25% in late-stage trial

[Incyte headquarters in Wilmington, Delaware, USA] JHVEPhoto/iStock Editorial via Getty Images Incyte’s (INCY [https://seekingalpha.com/symbol/INCY]) immunotherapy Monjuvi, developed with Xencor (XNCR [https://seekingalpha.com/symbol/XNCR... Full story

Yahoo Finance • 2 months ago

JPMorgan sees biotech sector at inflection point, resumes coverage on 14 Firms

Investing.com -- JPMorgan has reinstated ratings and price targets on 14 large-cap biotechnology companies, describing the sector as being at a critical “inflection point” as pipeline successes increasingly translate into profitable commer... Full story

Yahoo Finance • 2 months ago

Incyte (INCY) Positioned to Offset Patent Cliff Risks, Analysts Reaffirm Stock Ratings

Incyte Corporation (NASDAQ:INCY) ranks among the most profitable biotech stocks to buy now. On April 15, H.C. Wainwright restated Incyte Corporation (NASDAQ:INCY)’s Buy rating and $135 price target. The firm stated that Incyte’s povorcitin... Full story

Yahoo Finance • 2 months ago

Healthcare earnings impress with 86% beat rate, yet sector lags: Earnings Scorecard

[Magnifying Glass On Top Of Bar Chart] DNY59 Out of 22 S&P 500 healthcare companies that reported results this week, 19 beat earnings expectations and 15 posted year-over-year EPS growth. All 22 companies recorded year-over-year revenue i... Full story

Yahoo Finance • 3 months ago

Incyte Corp (INCY) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Promising ...

This article first appeared on GuruFocus. Total Revenue: $1.27 billion, up 21% year-over-year. Net Sales: $1.1 billion, representing 20% growth year-over-year. Jakafi Sales: $758 million, up 7% year-over-year. Opzelura Sales: $143 million... Full story

Yahoo Finance • 3 months ago

Incyte Q1 26 Earnings Conference Call At 8:00 AM ET

(RTTNews) - Incyte Corporation (INCY) will host a conference call at 8:00 AM ET on April 28, 2026, to discuss Q1 26 earnings results. To access the live webcast, log on to https://investor.incyte.com To listen to the call, dial 877-407-3... Full story

Yahoo Finance • 3 months ago

Incyte Reports First Quarter 2026 Financial Results and Provides Business Updates

Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% respectively, compared to the first quarter of 2025 Jakafi® (ruxolitinib) net sales of $758 million, an increase... Full story